In addition, the treatment of lung cancer using these mutations has changed remarkably.[4] In particular, EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have been reported in a randomized-controlled phase-3 trial to prolong the progression-free survival (PFS) and to improve the quality of life (QOL) when compared to conventional platinum-based chemotherapy.[5,6]. Here, EGFR is linked to lung carcinoma.